Article
Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
Leukemia - 1 Apr 2020
Baumeister Julian, Chatain Nicolas, Hubrich Annika, Maié Tiago, Costa Ivan G, Denecke Bernd, Han Lijuan, Küstermann Caroline, Sontag Stephanie, Seré Kristin, Strathmann Klaus, Zenke Martin, Schuppert Andreas, Brümmendorf Tim H, Kranc Kamil R, Koschmieder Steffen, Gezer Deniz
Abstract excerpt
Classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic malignancies including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The JAK2V617F mutation plays a central role in these disorders and can be found in 90% of PV and ~50-60% of ET and PMF. Hypoxia-inducible factor 1 (HIF-1) is a master transcriptional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.